Compare Recursion Pharmaceuticals’ AI driven push into FAP with a curated set of other algorithm powered healthcare opportunities by scanning 36 healthcare AI stocks before the next wave of data driven catalysts hits.
To own Recursion Pharmaceuticals, you need to believe its AI driven discovery engine can be converted into real products and recurring collaboration revenue before cash and dilution pressures dominate the story. The REC 4881 Phase 3 alignment strengthens that belief by showing the platform can generate programs that reach registrational design, but it does not change the near term cash burn, losses, or dependence on milestone timing that the analyst consensus Narrative on Simply Wall St already flags.
The most important short term catalyst still sits with continued TUPELO data readouts and any new or expanded partnerships that bring in non dilutive cash. The largest risk remains execution slippage that delays milestones while operating expenses stay high, forcing further equity raises on a stock that has already declined sharply over 1 and 3 years and recently diluted holders in a US$200 million offering.
The Jefferies London Healthcare Conference appearance is the other relevant recent event because it gives Recursion Pharmaceuticals a platform to frame the REC 4881 Phase 3 plan, TUPELO data and its wider AI foundation models story directly to institutional investors and potential partners. Conference slots rarely move the operating outlook by themselves, but they shape how upcoming trial and deal news might be received.
For catalysts, that kind of visibility matters when revenue was US$7.7 million in a recent quarter and fell 60% year over year, losses remain heavy at US$0.25 per share in Q2 2026, and the stock trades around US$2.72 after a multi year decline. Effective communication around the REC 4881 path, Sanofi or Roche or Genentech milestones, and expense discipline can influence how much flexibility Recursion has if it needs more capital before any late stage asset generates material cash flow.
Recursion Pharmaceuticals' narrative projects US$116.3 million revenue and US$20.7 million earnings by 2029. This implies 28.5% yearly revenue growth and an earnings increase of about US$539.6 million from a loss of US$518.9 million today.
Uncover why Recursion Pharmaceuticals' fair value indicates a 169% potential upside to its current price, and how that kind of gap may not last long.
One alternate angle on Recursion Pharmaceuticals focuses on cash pressure rather than REC-4881’s scientific promise. The most bearish analysts were working off forecasts of only US$25.3 million revenue and US$4.4 million earnings by 2029, paired with a very high implied P/E. Those expectations show how sharply views can differ; it can help to compare several narratives before deciding how this new Phase 3 design might reshape the story.
Explore 6 other Recursion Pharmaceuticals fair value estimates, including one that suggests as much as 28% downside from the current price.
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
Once you have a view on Recursion Pharmaceuticals, it can help to line it up against other opportunities that fit different roles in your portfolio, from higher yield to more defensive balance sheets or potential underappreciated stories.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com